skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery

(3259) Views  (1013) Full article downloads

Authors: M Nardi, C Lobo, A Bereczki, J Cano, E Zagato et al

Published Date January 2007 Volume 2007:1(4) Pages 527 - 533
DOI: http://dx.doi.org/10.2147/OPTH.S

M Nardi1, C Lobo2, A Bereczki3, J Cano4, E Zagato5, S Potts6, G Sullins6, R Notivol7, for the International C-04-65 Study Group*

1Neuroscienze-Clinica Oculistica, Università degli Studi di Pisa, Pisa, Italy; 2AIBILI, Coimbra, Portugal; 3Ophthalmology, Petz Aladár Hospital, Györ, Hungary; 4Oftalmología, Hospital Municipal, Badalona, Spain; 5Alcon Italia, Milan, Italy; 6R&D, Alcon Research Ltd., Fort Worth, TX, USA; 7Alcon Cusí, SA, Barcelona, Spain *Members of the International C-04-65 Study Group are listed in the Acknowledgments

Background: To compare nepafenac 0.1% with placebo and ketorolac 0.5% for prevention and treatment of ocular pain and inflammation after cataract surgery.

Methods: In a multi-center, randomized, placebo- and active-controlled, double-masked clinical trial, 227 patients with cataract were randomized to receive nepafenac 0.1%, ketorolac 0.5%, or placebo TID beginning 1 day pre-operatively and continuing for 21 days postoperatively. At each postoperative visit, cure rates and clinical success rates (≤5 aqueous cells and no flare) were calculated, and investigators evaluated patients’ pain. On Day 7, patients judged ocular comfort after study drug instillation.

Results: Nepafenac 0.1% produced significantly more cures compared to placebo at Day 14 (76.3% vs 59.2%, p = 0.0241), more clinical successes from Day 7 onward (p 0.05), and more pain-free patients from Day 3 onward (p 0.05). Nepafenac 0.1% was superior to ketorolac 0.5% in terms of clinical success at Day 14 (p = 0.0319) and in percentage of pain-free patients at Day 3 (p = 0.0366). Nepafenac 0.1% also demonstrated less discomfort upon instillation than ketorolac 0.5% (p = 0.0158).

Conclusion: The anti-inflammatory efficacy of nepafenac 0.1% is better than that of placebo; it is also more comfortable and at least equal to ketorolac 0.5% in the prevention and treatment of postoperative ocular pain and inflammation.

Keywords: NSAIDs, cataract, inflammation, nepafenac, ketorolac








Readers of this article also read:

Topical nepafenac in the treatment of diabetic macular edema
Lens-induced glaucoma in the elderly
The pathophysiology of bronchiectasis
Corrigendum - Functional mobility and balance in community dwelling elderly submitted to multisensory versus strength exercises
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Central corneal thickness, intraocular pressure, and degree of myopia in an adult myopic population aged 20 to 40 years in southeast Spain: determination and relationships
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Association between optic nerve blood flow and objective examinations in glaucoma patients with generalized enlargement disc type
Challenges in the clinical measurement of ocular surface disease in glaucoma patients
The association between primary open-angle glaucoma and fall: an observational study